RTW Investments LP Invests $2.30 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

RTW Investments LP bought a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 148,844 shares of the company's stock, valued at approximately $2,300,000. RTW Investments LP owned 0.61% of Artiva Biotherapeutics as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth $42,000. MetLife Investment Management LLC bought a new position in Artiva Biotherapeutics during the third quarter valued at approximately $135,000. Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics in the 3rd quarter worth approximately $623,000. Finally, Acuta Capital Partners LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $680,000.

Artiva Biotherapeutics Trading Down 2.8 %

Shares of Artiva Biotherapeutics stock traded down $0.36 during trading on Thursday, hitting $12.36. 15,976 shares of the stock traded hands, compared to its average volume of 125,424. Artiva Biotherapeutics, Inc. has a 52-week low of $9.68 and a 52-week high of $17.31. The firm's fifty day moving average is $12.56.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24). Analysts forecast that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current year.

Analysts Set New Price Targets

ARTV has been the subject of several research reports. TD Cowen began coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a "buy" rating for the company. Needham & Company LLC reiterated a "buy" rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Jefferies Financial Group assumed coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a "buy" rating and a $21.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Finally, Cantor Fitzgerald assumed coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set an "overweight" rating and a $23.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $21.25.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.